Reig Jofre has published its financial results for 2023. The laboratory recorded sales of more than 315 million euros, 17% more than in 2022. The company indicates that this increase is also due to the manufacturing capacity provided by the new plant in Barcelona.
The Catalan laboratory has obtained an EBITDA of 35 million euros, 15% more than the previous year, where the figure stood at 30.4 million euros.
The consumer product division, Consumer Healthcare, accounted for 11% of sales with the FORTE PHARMA brand in the French, Belgian and Spanish markets and Reig Jofre's OTC products, which accounted for 10% of total turnover.
In the last quarter of the previous year, Reig Jofre achieved 237 million euros in sales, 22% more than in the previous quarters of the year. This increase in sales was led by a notable rise in the Specialty Pharmacare Division and higher capacity utilisation at the new Barcelona plant. Its Consumer Healthcare brand, the consumer products division with the Forte Pharma brand, and OTC products in the Spanish, French and Belgian markets, grew by 11%.